Edgewise Therapeutics (NASDAQ:EWTX – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $30.00 to $31.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock.
EWTX has been the subject of several other reports. Piper Sandler reissued an overweight rating and issued a $48.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 1st. Wedbush restated an outperform rating and set a $31.00 price target on shares of Edgewise Therapeutics in a research note on Wednesday, June 26th. Truist Financial restated a buy rating and set a $25.00 price target on shares of Edgewise Therapeutics in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada restated an outperform rating and set a $32.00 price target on shares of Edgewise Therapeutics in a research note on Thursday, July 25th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Edgewise Therapeutics presently has a consensus rating of Buy and a consensus price target of $33.40.
Get Our Latest Analysis on Edgewise Therapeutics
Edgewise Therapeutics Trading Down 0.2 %
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. Research analysts predict that Edgewise Therapeutics will post -1.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. RA Capital Management L.P. purchased a new position in Edgewise Therapeutics in the first quarter worth $162,502,000. Baker BROS. Advisors LP raised its position in Edgewise Therapeutics by 87.6% in the first quarter. Baker BROS. Advisors LP now owns 5,840,059 shares of the company’s stock worth $106,523,000 after acquiring an additional 2,727,273 shares in the last quarter. Vanguard Group Inc. raised its position in Edgewise Therapeutics by 89.0% in the first quarter. Vanguard Group Inc. now owns 4,017,433 shares of the company’s stock worth $73,278,000 after acquiring an additional 1,892,053 shares in the last quarter. Frazier Life Sciences Management L.P. raised its position in Edgewise Therapeutics by 214.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 2,667,203 shares of the company’s stock worth $29,179,000 after acquiring an additional 1,818,181 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in Edgewise Therapeutics by 48.6% in the first quarter. Janus Henderson Group PLC now owns 1,805,312 shares of the company’s stock worth $32,898,000 after acquiring an additional 590,299 shares in the last quarter.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
See Also
- Five stocks we like better than Edgewise Therapeutics
- How to Buy Cheap Stocks Step by Step
- Brinker International’s Price Dip is an Appetizing Entry Point
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Stocks That Could Beat the September Blues
- Dividend Payout Ratio Calculator
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.